Yen T T
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202-5122, USA.
Obes Res. 1995 Nov;3 Suppl 4:531S-536S. doi: 10.1002/j.1550-8528.1995.tb00223.x.
In the past decade, the antiobesity, antidiabetic and nutrient partitioning activities of beta-agonists have been extensively studied. The data generated from these compounds in experimental and farm animals have convincingly proved that body fat content and body weight can be modified to some degree by a metabolic agent without decreasing food consumption. Marginal antiobesity and antidiabetic activities in humans have been demonstrated with a few mixed beta-agonists under certain conditions, but their utility is limited by side effects. The concept of a beta 3-receptor rose from the study of these compounds and has been verified by the cloning and expression of this receptor from several species. Rat beta 3-selective agonists have so far shown no antiobesity efficacy in humans. The resolution of several issues is critical for the discovery and development of efficacious antiobesity and antidiabetic agents with minimum side effects. Ultimately, the further investigation of these beta-agonists and beta-receptors should lead to a better understanding of the relationship between energy metabolism and feeding behavior.
在过去十年中，β-激动剂的抗肥胖、抗糖尿病和营养分配活性得到了广泛研究。从这些化合物在实验动物和农场动物身上获得的数据令人信服地证明，一种代谢剂可以在不减少食物摄入量的情况下，在一定程度上改变体脂含量和体重。在某些条件下，少数混合β-激动剂已在人体中显示出边际抗肥胖和抗糖尿病活性，但其效用受到副作用的限制。β3受体的概念源于对这些化合物的研究，并已通过从多个物种克隆和表达该受体得到验证。迄今为止，大鼠β3选择性激动剂在人体中尚未显示出抗肥胖功效。解决几个问题对于发现和开发具有最小副作用的有效抗肥胖和抗糖尿病药物至关重要。最终，对这些β-激动剂和β-受体的进一步研究应有助于更好地理解能量代谢与摄食行为之间的关系。
